Cohance Lifesciences Ltd

Cohance Lifesciences Ltd commenced trading on 3 Feb 2026 with a notable gap up, opening 5.01% higher than its previous close, signalling a robust start amid positive market conditions in the Pharmaceuticals & Biotechnology sector.

Cohance Lifesciences Ltd’s shares declined to a fresh 52-week low of Rs.355.65 on 2 Feb 2026, marking a significant downturn amid broader market gains. The stock has underperformed its sector and benchmark indices, reflecting ongoing pressures on its valuation and financial metrics.

Cohance Lifesciences Ltd, a key player in the Pharmaceuticals & Biotechnology sector, recorded a new 52-week low of Rs.367.35 today, marking a significant decline in its stock price amid broader market volatility and sector underperformance.

Cohance Lifesciences Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.368.5 today, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on its valuation and performance metrics.

Cohance Lifesciences Ltd, a player in the Pharmaceuticals & Biotechnology sector, recorded a new 52-week low of Rs.369.5 today, marking a significant decline amid broader market pressures and company-specific performance factors.

Cohance Lifesciences Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has declined to a fresh 52-week low of Rs.379.25, marking a significant drop in its share price amid broader market weakness and sector underperformance.

Cohance Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Cohance Lifesciences Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.380 today, marking a significant decline amid a prolonged downtrend. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on its valuation and performance metrics.

Cohance Lifesciences Ltd’s shares declined to a fresh 52-week low of Rs.407.8 on 20 Jan 2026, marking a significant downturn amid a broader market pullback. The stock has now recorded an eight-day consecutive fall, accumulating a loss of 18.76% over this period, underperforming its sector and the broader market indices.

Cohance Lifesciences Ltd touched a new 52-week low of Rs.415 today, marking a significant decline amid a sustained downtrend that has seen the stock underperform the broader market and its sector peers over the past year.

Cohance Lifesciences Ltd has touched a new 52-week low of Rs.441.2 today, marking a significant decline amid a sustained downward trajectory. The stock has underperformed its sector and broader market indices, reflecting a challenging period for the pharmaceuticals and biotechnology company.

Cohance Lifesciences Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has declined to a fresh 52-week low of Rs.458.1, marking a significant downturn in its stock performance amid broader market resilience.

Cohance Lifesciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 31 December 2025, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 12 January 2026, providing investors with the latest perspective on the company’s position in the market.

Cohance Lifesciences Ltd has touched a new 52-week low of Rs.478 today, marking a significant decline in its stock price amid ongoing downward momentum. The stock has underperformed its sector and broader market indices, reflecting a challenging period for the pharmaceuticals and biotechnology company.

Cohance Lifesciences Ltd has touched a new 52-week low of Rs.494.7 today, marking a significant decline in its stock price amid broader market weakness and company-specific performance concerns. The stock underperformed its sector and continues to trade below all key moving averages, reflecting ongoing pressures in the Pharmaceuticals & Biotechnology industry.

Cohance Lifesciences Ltd touched a new 52-week low of Rs.499 today, marking a significant decline in its stock price amid a sustained downtrend. This latest low comes as the pharmaceutical and biotechnology company continues to face multiple headwinds, reflected in its recent financial performance and market valuation metrics.

Cohance Lifesciences Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.499 today, marking a significant decline in its stock price amid broader market fluctuations and company-specific performance factors.

Cohance Lifesciences Ltd has touched a new 52-week low of Rs.506.25 today, marking a significant decline in its stock price amid broader market fluctuations. The pharmaceutical and biotechnology company’s shares have been under pressure, reflecting a series of financial and valuation concerns that have weighed on investor sentiment.